LUSTRAL

This brand name is authorized in Ireland, Israel, Turkey, United Kingdom

Active ingredients

The drug LUSTRAL contains one active pharmaceutical ingredient (API):

1 Sertraline UNII UTI8907Y6X - SERTRALINE HYDROCHLORIDE

Sertraline is a potent and specific inhibitor of neuronal serotonin (5-HT) uptake in vitro, which results in the potentiation of the effects of 5-HT in animals. It has only very weak effects on norepinephrine and dopamine neuronal reuptake. Read about Sertraline

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
LUSTRAL Film-coated tablet	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N06AB06	Sertraline	N Nervous system → N06 Psychoanaleptics → N06A Antidepressants → N06AB Selective serotonin reuptake inhibitors
Discover more medicines within N06AB06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 139273, 139275, 14222, 14223, 143752, 162039, 199683
Country: IE	Health Products Regulatory Authority	Identifier(s): 31345, 31380, 31399, 31561, 31582, 32343, 32576, 32577
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 2979, 4273
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699532090041, 8699532090140, 8699532095428, 8699532095473, 8699532096739, 8699532098603, 8699532099693